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Abstract Purpose:Treatment of tumor cells by chemotherapy activates a series of responses ranging from
apoptosis to premature senescence and repair. Survival responses are characterized by inhibition
of cyclin-dependent kinases. Because inhibitionof cyclin-dependent kinases represents a distinc-
tive feature of DNA damage ^ induced prosurvival responses, we investigated the possibility that
the cyclin-dependent kinase inhibitor roscovitine modulates drug-induced responses in human
adenocarcinoma cells, favoring cell survival.
Experimental Design: Sublethal concentrations of doxorubicin were used to induce premature
senescence in human adenocarcinoma cells. The effect of the cyclin-dependent kinase inhibitor
roscovitine on the doxorubicin-dependent cell cycle checkpoint activation and DNA repair path-
ways was evaluated.
Results: Roscovitine reinforces doxorubicin-dependent G1checkpoint in A549 and HEC1B cells
leading to decreased frequencyof double-strandbreaks and to thepreferential inductionof senes-
cence and enhanced clonogenic survival. However, in other tumor cell lines, such as HCT116 and
H1299, combined treatment with doxorubicin and roscovitine increases the frequency of double-
strand breaks and dramatically sensitizes to doxorubicin. This unexpected effect of roscovitine
depends on a novel ability to inhibit DNA double-strand break repair processes and requires inac-
tivation of the pRb pathway.
Conclusions: Roscovitine, by hindering DNA repair processes, has the potential to inhibit
recovery of mildly damaged tumor cells after doxorubicin treatment and to increase the suscep-
tibility of tumor cells to chemotherapy. However, in some tumor cells, the cell cycle inhibitory
function of roscovitine prevails over the DNA repair inhibitory activity, favoring premature senes-
cence and clonogenic growth. These data indicate a novel mechanism underlying combined
chemotherapy, which may have wide application in treatment of carcinomas.
Chemotherapy is the primary form of treatment for human
cancer. Conventional anticancer drugs damage several cellular
components, triggering a series of cellular responses. At high
doses of these drugs, the predominant effect is cell death,
whereas at low doses tumor cells may repair damage and
eventually resume normal proliferation (1). Cell death after
DNA damage is largely the result of apoptosis, and accordingly,
apoptosis is a key determinant of treatment outcome (2).
However, although apoptosis represents the main response to
chemotherapy in hematologic malignancies, the outcome of
therapy in solid tumors does not correlate with the extent of
programmed cell death (3). In solid tumors, treatment does not
lead to tumor regression but rather results in so-called stable
disease. The cytostatic effect of chemotherapeutic agents results
from the activation of a premature senescence program (1).
Accordingly, treatment of tumor cell lines with low doses of
DNA-damaging agents readily induces features of senescence
(4). More importantly, the induction of a senescent-like
phenotype by anticancer drugs can be induced in vivo and
contributes to successful treatment (5).
Factors that modulate stress-induced premature senescence
have not yet been extensively studied. Stress-induced senescent
cells acquire a distinctive morphology and the expression
of specific phenotypic markers, such as acidic senescence-
associated h-galactosidase (SA-h-gal). In addition, a distinctive
feature of senescent cells is the increased expression of cyclin-
dependent kinase (Cdk) inhibitors, which seems to be
responsible for the permanent cytostatic arrest. Inhibition of
Cdk activity also represents a key feature of DNA damage
checkpoints (6).
Roscovitine is a small molecule that inhibits Cdks via direct
competition in the ATP-binding site. It is particularly active
against Cdk1 (Cdc2), Cdk2, and Cdk5 (7) and induces G1 and
G2-M arrest in cells. High doses of roscovitine induce apoptosis
in tumor cells (8, 9). Because inhibition of Cdk activity
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represents a common feature of DNA damage– induced
prosurvival responses, we decided to investigate the possibility
that roscovitine modulates drug-induced damage responses
in human adenocarcinoma cells, favoring the activation of
senescence.
We show that roscovitine reinforces the G1 checkpoint in
doxorubicin-treated A549 and HEC1B cells. Augmentation of
G1 arrest reduces the extent of DNA damage and results in
the preferential induction of a senescence program and in a
chemoprotective effect of roscovitine. However, in several other
human adenocarcinoma cells studied, roscovitine treatment
dramatically sensitizes cells to doxorubicin-induced DNA
damage. The ability of roscovitine to greatly sensitize certain
tumor cells to DNA damage seems to require an inactive pRb
pathway. These data indicate a novel mechanism underlying
combined chemotherapy, which may have wide application in
treatment of carcinomas.
Materials andMethods
Cell cultures and drug treatment. A549, HEC1B, HCT116, SW480,
and H1299 cell lines were obtained from American Type Culture
Collection (Rockville, MD) and cultured according to its instructions.
MCF-7 and HeLa cells were cultured in DMEM, and MDA-MB-231 cells
were cultured in RPMI. All media were supplemented with 10% FCS.
Cell culture media and reagents were purchased by Invitrogen (San
Giuliano Milanese, Milan, Italy). Doxorubicin (Calbiochem, San Diego,
CA) was dissolved in sterile water (5 mg/mL stock solution).
Roscovitine (Calbiochem) was dissolved in DMSO (5 mg/mL stock
solution).
Growth assay and colony-forming efficiency. Cells were plated in
triplicate at 2 104 per well in a 24-well plate. After 16 hours, cells were
treated with roscovitine (10 Amol/L) or DMSO (vehicle). Cell number
was assessed using a hemocytometer. Trypan blue (0.08%; Sigma,
Milan, Italy) was added to evaluate cell viability. For colony-forming
assay, cells were plated in triplicate at 5  104 in 60-mm dishes. After
8 to 10 days, colonies were stained with 1% methylene blue in 50%
ethanol.
Senescence-associated b-galactosidase activity. Staining for SA-h-gal
was done as described previously (10). Routinely, cells were plated in
triplicate at 5  104 in 35-mm dishes or at 1  105 in 60-mm dishes.
Immunofluorescence microscopy. Cells were grown onto glass cover-
slips in six-well multidishes and allowed to adhere for 16 hours. Cells
were fixed with methanol (20jC) and permeabilized with ice-cold
acetone. Cells were blocked with 10% fetal bovine serum in TBS-0.1%
Tween 20 for 15 minutes. Phosphorylated histone H2AX (g-H2AX) was
detected by incubating the cells with anti-g-H2AX monoclonal
antibody in a 1:200 dilution for 2 hours. Cells were washed with
TBS-0.1% Tween 20 and then incubated with 1:500 dilution of
fluorescein-tagged goat anti-mouse secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). After washes with TBS-0.1% Tween 20,
the coverslips were mounted on a microscope slide using a 90%
solution of glycerol in TBS and analyzed with a Zeiss Axioplan
microscope. g-H2AX foci were counted visually in >100 cells by
capturing images of randomly chosen fields. Cells with >20 foci were
excluded from quantitative analyses.
Flow cytometry for g-H2AX. Cells were fixed with ethanol and
routinely kept at 20jC overnight. Cells were washed twice with TBS
and permeabilized with TBS, 4% fetal bovine serum, 0.1% Triton X-100
for 10 minutes on ice. Cells were washed with TBS and incubated with
anti-g-H2AX monoclonal antibody in a 1:200 dilution in TBS, 4% fetal
bovine serum, for 2 hours. Cells were washed twice with TBS-0.1%
Tween 20 and incubated with 1:200 dilution of fluorescein-tagged goat
anti-mouse secondary antibody. After washes with TBS-0.1% Tween 20,
cells were resuspended in TBS and analyzed using a FACScan cell
scanner (Becton Dickinson, Franklin Lakes, NJ). Data were analyzed by
the CellQuest software (BD Biosciences, Franklin Lakes, NJ).
Western blot analysis. Total cell proteins preparations were obtained
lysing cells by 1 mmol/L EDTA, 0.2% Triton X-100, 1 Ag/mL aprotinin,
170 Ag/mL phenylmethylsulfonyl fluoride, and phosphatase inhibitors
(Sigma). Protein concentration was routinely measured by the Bio-Rad
protein assay (Milan, Italy). Polyacrylamide gels (7.5-15%) were
prepared essentially as described by Laemmli (11). Molecular weight
standards were from New England Biolabs (Hitchin, Herts, United
Kingdom). Proteins separated on the polyacrylamide gels were blotted
onto nitrocellulose filters (Hybond-C, Amersham, Bucks, United
Kingdom). Filters were washed and stained with specific primary
antibodies and then with secondary antisera conjugated with horserad-
ish peroxidase diluted (1:2,000; Bio-Rad). Filters were developed using
the enhanced chemiluminescence Western blotting detection reagent
(Amersham) and quantitatively estimated by scanning with a Discover
Pharmacia scanner equipped with a Sun Spark Classic Workstation. The
anti-Bcl-2 (100), Bcl-X (S-18), Mcl-1 (S-19), Bax (N-20), p27KIP1 (C-19),
p21CIP1 (C-19), cyclin E (M20), cyclin A (C-19), Cdk2 (M2), Cdk1 (17),
p16INK4a (C-20), and p53 (DO-1) antibodies were purchased from
Santa Cruz Biotechnology; anti-pRb (554136) was from BD Phar-
Mingen (Franklin Lakes, NJ); antibodies specific for the phosphorylated
state of Ser807, Ser795, and Ser807/Thr811 in pRb were from New England
Biolabs; anti-g-H2AX (JBW301) was from Upstate Biotechnology
(Milton Keynes, United Kingdom); anti-Ku70, anti-Ku80, and anti-a-
tubulin antibodies were from Serotec (Oxford, United Kingdom).
Cell cycle and apoptosis analyses. Flow cytometric analysis was as
described by Nicoletti et al. (12). Cells were analyzed on a FACScan cell
scanner. Data were analyzed by the ModFit/LT (Verity Software,
Topsham, ME).
In vivo recombination assay system and analysis of homologous
recombination frequency. HeLa cells carrying a single integrated copy
of a green fluorescent protein (GFP) recombination reporter construct
were a gift from Prof. E. Avvedimento (Universita` di Napoli ‘‘Federico II,’’
Naples, Italy). This reporter construct contains two GFP genes: one
nonfunctional GFP gene mutated to contain a I-SceI cleavage site
and an additional, truncated GFP gene that can correct the SceI site
mutation. The I-SceI restriction endonuclease is used to introduce a
double-strand break (DSB) in the reporter gene. Chromosomal repair of
the reporter gene by homologous recombination leads to GFP
expression, which is analyzed by flow cytometry. To examine the effect
of roscovitine on DSB-induced homologous recombination, HeLa cells
were transiently transfected with the I-SceI expression vector pCAGGS-I-
SceI (gift from Prof. E. Avvedimento) or with a cytomegalovirus (CMV)
empty vector. Routinely, cells at f60% confluence were transfected
using LipofectAMINE reagent (Invitrogen) following the manufacturer’s
protocol. DNA (2 Ag) per 60-mm dish was used. Roscovitine was added
to the medium 6 hours after the addition of constructs. Seventy-two
hours after the addition of constructs, the percentage of GFP-positive cells
was determined by flow cytometry on a Becton Dickinson FACScan. To
examine the effect of dominant-negative (dn) Cdk2 (dn-K2) or Cdk1
(dn-K1) on homologous recombination, HeLa-HR-GFP cells were
cotransfected with the I-SceI expression vector pCAGGS-I-SceI and with
a vector expressing either dn-K2 or dn-K1 or control empty vector (13) in
a 1:1 ratio. The percentage of GFP-positive cells was determined 72 hours
after the addition of constructs. To examine the effect of Cdk2, HeLa-HR-
GFP cells were cotransfected with the I-SceI expression vector pCAGGS-I-
SceI and with either a CMV control vector or the same vector expressing
Cdk2 (13) in a 1:1 or 1:2 ratio. The percentage of GFP-positive cells was
determined 72 hours after the addition of constructs.
Evaluation of DNA-dependent protein kinase activity. DNA-depen-
dent protein kinase (DNA-PK) activity was estimated by using
SignaTECT DNA-PK assay system (Promega, Milan, Italy) following
the manufacturer’s protocol. Routinely, DNA-free nuclear extracts (200-
500 ng) were incubated with biotinylated peptide substrate, [g-32P]ATP,
and either DNA-PK activation buffer or DNA-PK control buffer for
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5 minutes at 30jC. Termination buffer was added, and the reaction
sample (10 AL each) was spotted onto a SAM2TM biotin capture
membrane. The SAM2TM membrane squares were washed and dried
before analysis by scintillation counting. The enzymatic activity of
DNA-PK was calculated according to the SignaTECT protocol and
normalized to the amount of Ku80 protein.
Results
Induction of premature senescence in A549 lung adenocar-
cinoma cell line. To investigate the ability of roscovitine to
modulate drug-induced premature senescence, we first exposed
the human adenocarcinoma cell line A549 to moderate doses
of doxorubicin. Doxorubicin is a widely used chemotherapeutic
agent believed to act primarily by stabilizing topoisomerase
II-DNA complexes (14). The cellular damage is related to the
accumulation of DNA DSBs. Exposure of tumor-derived cell
lines to doxorubicin has been reported to induce premature
senescence (4). Hence, we incubated A549 cells with 50 nmol/L
doxorubicin for 48 hours, after which the cells were extensively
washed and cultured in drug-free medium. After 8 days in the
absence of the drug, two different types of cells were detected:
normal proliferating cells, which gave rise to colonies (Fig. 1A),
and cells with enlarged and flattened morphology, which
stained positive for SA-h-gal (Fig. 1B). To confirm the inability
of doxorubicin-induced senescent cells to proliferate, we
labeled the cells with PKH2 (15). A significant fraction of
highly fluorescent permanently growth-arrested cells was
detected 8 days after labeling (data not shown). These data
indicate that low doses of doxorubicin induce premature
senescence in a substantial fraction of A549 cells.
Whereas senescence is readily induced by low doses of DNA-
damaging agents, apoptosis seems to be preferentially induced
at high doses. We assessed the effect of 50 nmol/L doxorubicin
on apoptosis in A549 cells by flow cytometry. No observable
increase in the sub-G1 population was observed in doxorubicin-
treated cells compared with controls (Fig. 2C; data not shown).
In addition, analysis of molecular markers of apoptosis did not
indicate induction of apoptosis (data not shown). Hence, the
dose of doxorubicin selected for this study does not induce
apoptosis but does induce mainly premature senescence and
recovery.
Effect of roscovitine on proliferation and viability. Pharma-
cologic inhibitors of Cdks induce apoptosis in several tumor
cell lines (8, 9). To avoid a cytotoxic effect of roscovitine in the
combined treatments, we chose a concentration of the drug
(10 Amol/L) that inhibits cell proliferation but does not induce
cell death. As shown in Fig. 1C and D, 10 Amol/L roscovitine
significantly inhibited cell proliferation, increasing doubling
time from 24 tof31 hours. However, cell viability, assessed by
trypan blue exclusion assay and by flow cytometry, was not
affected (Fig. 1C and D; data not shown).
Roscovitine increases doxorubicin-induced premature senes-
cence and cell recovery after drug release. To evaluate the
ability of roscovitine to modulate cellular responses to
doxorubicin, A549 cells were incubated for 48 hours either
with doxorubicin alone or with doxorubicin combined with
roscovitine. Cells were then released and recultured in drug-free
medium for 8 days. Treatment of cells with roscovitine plus
doxorubicin increased the fraction of SA-h-gal-positive cells
by f30% compared with doxorubicin alone (Fig. 2A;
P < 0.001). The effect of roscovitine on clonogenic survival
was then investigated. These experiments showed a significant
increase in colony formation when roscovitine was used in
combination with doxorubicin (Fig. 2B; P < 0.05). These results
show that roscovitine protects A549 cells exposed to a sublethal
dose of DNA-damaging agent.
Fig. 1. Effects of doxorubicin and roscovitine in
A549 cells.A andB, triplicate samples of A549 cells
were incubated with doxorubicin for 48 hours. Cells
were replated in drug-free medium. After10 days,
cells were stained to detect SA-h-gal activity.
A, normal proliferating cells; B, morphologic
alterations in senescent cells.C andD, effect of
10 Amol/L roscovitine on proliferation and viability in
A549 cells. Cells were stained with trypan blue and
counted at indicated times. Columns, mean cell
number; bars, SE. Population doubling time (PDL) is
shown for each condition.
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Reinforcement of G1 arrest in doxorubicin-treated cells by
roscovitine. To determine the effect of roscovitine and
doxorubicin on cell cycle distribution, cells were treated either
with the two drugs alone or in combination and were analyzed
by flow cytometry (Fig. 2C). Roscovitine alone only slightly
affected the cell cycle distribution of A549 cells. Incubation
with doxorubicin resulted in accumulation of cells in G2-M
phase of the cell cycle likely due to activation of the G2
checkpoint (16). The accumulation of cells in G2-M was
reduced in cells treated with doxorubicin plus roscovitine and
was accompanied by a concomitant increase of cells in G1
phase. Increased number of G1 cells in combined treatment
may indicate either a reinforcement of G1 checkpoint or an
abrogation of G2 checkpoint by roscovitine. Therefore, we
examined the effect of nocodazole on cell cycle distribution of
treated cells. Nocodazole did not revert the effect of roscovitine
(data not shown), indicating that roscovitine reinforces of G1
checkpoint.
The ability of roscovitine to modulate G1 cell cycle
checkpoint might either depend on a direct inhibition of Cdk
activity or on the modulation of cell cycle inhibitory proteins.
To discriminate between these two possibilities, we examined
Fig. 2. Effect of combined treatment on senescence, clonogenic survival, cell cycle, and cell cycle regulators of A549 cells.A, triplicate samples of A549 cells were incubated
either with doxorubicin (doxo) or with roscovitine + doxorubicin (d+R) for 48 hours. Cells were replated in drug-free medium. After10 days, cells were stained to detect
SA-h-gal activity.The amount of senescent cells was determined by counting of three random fields. Columns, mean of three independent experiments; bars, SE. P < 0.001,
unpaired Student’s t test. B, triplicate samples of A549 cells were incubated either with doxorubicin or with roscovitine + doxorubicin for 48 hours. Cells were replated in
drug-freemedium.After 8 days, colonieswere stainedwithmethylene blue.P < 0.05, unpaired Student’s t test.C, cellswere incubatedwith roscovitine, doxorubicin, or both for
48 hours. Numbers, percentage of cells in G1, S, or G2-M phase.D, A549 cells were incubated with roscovitine (R), doxorubicin (d), or both (d+R) for 48 hours and protein
expressionwas detected byWestern blot. Filters were stripped and reprobed with anti-a-tubulin antibodies as loading control.
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Fig. 3. Effects of doxorubicin and roscovitine in H1299 cells.A, effect of10 Amol/L roscovitine on proliferation and viability in H1299 cells. Cells were stained with trypan
blue and counted at indicated times. Columns, mean cell number; bars, SE. Population doubling time (PDL) is shown for each condition. B, morphologic alterations and
SA-h-gal staining in H1299 cells.Triplicate samples of H1299 cells were incubated either with doxorubicinor with doxorubicin + roscovitine for 48 hours. Cells were replated in
drug-free medium. After10 days, cells were stained to detect SA-h-gal activity. Small arrows, morphologic alterations in senescent cells; large arrows, normal proliferating
cells.C, p21CIP accumulation in doxorubicin-treated H1299 cells. Filters were stripped and reprobed with anti-a-tubulin antibodies as loading control.D, effect of combined
treatment on cell cycle. Cells were incubated with roscovitine, doxorubicin, or both for 48 hours. Numbers, percentage of cells in G1, S, or G2-M phase.
Cancer Therapy: Preclinical
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the levels of cell cycle regulatory proteins. Incubation of A549
cells with the two drugs alone or in combination did not affect
the level of expression of p53 as evaluated by Western blot
(Fig. 2D). However, p21CIP was clearly induced in doxorubicin-
treated cells, although no differences in p21CIP protein levels
were detected between cells treated with doxorubicin only and
cells treated with doxorubicin plus roscovitine (Fig. 2D).
Protein levels of p27KIP were slightly reduced by doxorubicin
(Fig. 2D). Consistent with the accumulation of Cdk inhibitor
p21CIP, Western blot analyses using a pan-pRb antibody
showed an accumulation of the hypophosphorylated, active
isoforms of the protein in cells incubated with doxorubicin and
in combined treatments (Fig. 2D). Antibodies specific for the
phosphorylated state of Ser780, Ser795, and Ser807/Thr811
confirmed the reduced phosphorylation of pRb (Fig. 2D).
These data suggest that the ability of roscovitine to reinforce G1
checkpoint depends on direct inhibition of Cdks.
Effects of roscovitine and doxorubicin on H1299 cells. To
extend the above observation to additional cell lines, we
decided to investigate the effects of roscovitine in a p53/
background, for which we used a lung adenocarcinoma cell
line, H1299. We first evaluated the effects of low concentrations
of roscovitine (10 Amol/L) on cell proliferation. As shown in
Fig. 3A, 10 Amol/L roscovitine slightly inhibited proliferation of
H1299 cells. In addition, viability of the cells monitored either
by trypan blue exclusion method (Fig. 3A) or by fluorescence-
activated cell sorting analyses (Fig. 3D) was not affected by low
doses of roscovitine. Therefore, as for A549 cells, low doses
of roscovitine did not activate an apoptotic response in the
H1299 cell line.
We then investigated the capacity of doxorubicin to induce
premature senescence in H1299 cells. H1299 cells do not
express either p53 or p16INK4a; however, it has been shown
previously that inactivation of p53 and p16INK4a pathways
does not completely abolish stress-induced senescence res-
ponse in carcinoma cells (15). We exposed H1299 cells to
50 nmol/L doxorubicin for 48 hours, after which the cells
were extensively washed and cultured in drug-free medium for
8 days. Morphologically altered cells, which stained positive
for SA-h-gal, were easily detected in doxorubicin-treated dishes
(Fig. 3B). Hence, treatment with low-dose doxorubicin
induces features of premature senescence in H1299 cell line.
Analysis of cell cycle regulators shows a marked accumulation
of p21CIP in cells treated with doxorubicin (Fig. 3C). However,
no differences in p21CIP protein levels were detected between
cells treated with doxorubicin only and cells treated with
Fig. 4. Effects of roscovitine and dn-K2 inH1299 cells.A, effect of roscovitine on senescence.Triplicate samples ofH1299 cellswere incubatedeither with doxorubicinor with
roscovitine + doxorubicin for 48 hours. Cells were replated in drug-free medium. After10 days, cells were stained to detect SA-h-gal activity.The amount of normal (black)
and senescent (gray) cellswas determinedbycountingof three random fields. Columns,meanof three independent experiments; bars, SE.P < 0.001, for normal cells (unpaired
Student’s t test). B, effect of roscovitine on clonogenic survival.Triplicate samples of H1299 cells were incubated either with doxorubicin or with roscovitine + doxorubicin
for 48 hours. Cells were replated in drug-free medium. After 8 days, colonies were stained with methylene blue. Columns, mean of three independent experiments; bars, SE.
P < 0.01, unpaired Student’s t test. C, effect of dn-K2 on senescence.Triplicate samples of H1299 cells were pretreated with doxycycline for 24 hours and subsequently
incubated with doxorubicin for 48 hours. Cells were replated in drug-free medium. After10 days, cells were stained to detect SA-h-gal activity.The amount of normal and
senescent cells was determined by counting of three random fields. P < 0.001, for normal cells (unpaired Student’s t test).D, effect of dn-K2 on clonogenic survival.Triplicate
samples of H1299 cells were pretreated with doxycycline for 24 hours and subsequently incubatedwith doxorubicin for 48 hours. Cells were replated in drug-free medium.
After 8 days, colonies were stained with methylene blue.
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doxorubicin plus roscovitine (Fig. 3C). Because neither p53
nor p16INK4a are expressed in H1299 cells, the observed
accumulation in p21CIP is likely to be responsible for the
induction of premature senescence following treatment with
doxorubicin.
Roscovitine increases doxorubicin-dependent G2 accumulation
in H1299 cells. H1299 cells were treated with either
roscovitine or doxorubicin alone or in combination for 48
hours and then analyzed by flow cytometry. As shown in
Fig. 3D, treatment with low doses of roscovitine had no major
effect on cell cycle distribution of asynchronously growing
H1299 cells. As already observed in the A549 cell line,
doxorubicin-treated cells largely accumulated in the G2-M
phase. However, unlike A549 cells, simultaneous treatment
with roscovitine and doxorubicin favored the G2-M accumula-
tion of H1299 cells (Fig. 3D).
These results suggest that the ability of roscovitine to
modulate doxorubicin-dependent checkpoints may vary in
different cell lines.
Roscovitine inhibits recovery of H1299 cells after drug removal
without affecting premature senescence. Roscovitine differen-
tially affects the cell cycle distribution of doxorubicin-treated
A549 and H1299 cells. To evaluate if this difference results
in a different treatment outcome, H1299 cells were incubated
either with doxorubicin alone or with doxorubicin plus
roscovitine. Cells were then cultured in drug-free medium for
8 days and the number of normal versus senescent cells was
estimated. As shown in Fig. 4A, the combination of roscovitine
and doxorubicin dramatically reduced the number of normal
proliferating cells (P < 0.001) while not affecting the number of
senescent cells. Furthermore, combined treatment markedly
inhibited the clonogenic survival of H1299 cells compared with
doxorubicin-treated cells (Fig. 4B; P < 0.01).
These data show that roscovitine sensitizes H1299 cells to
doxorubicin-dependent DNA damage. The differential effect
observed in A549 versus H1299 cells suggests that the ability of
roscovitine to reinforce the G1 checkpoint substantially affects
cell fate.
Expression of dominant-negative cyclin-dependent kinase 2
increases doxorubicin-dependent G2 arrest and inhibits cell
recovery after drug release. Pleiotropic effects of roscovitine
have been reported in human tumor cell lines. Roscovitine has
been shown to induce nucleolar fragmentation (17), p53
nuclear translocation (17), activation of mitogen-activated
Fig. 5. Effects of roscovitine on histone H2AX phosphorylation in A549 cells. A, A549 cells were incubated with doxorubicin for 48 hours in the presence or absence of
roscovitine. Cells were immunostained with an anti-g-H2AXmonoclonal antibody followed by secondary fluorescein conjugate antibodies. Nuclei were stained with
4V,6-diamidino-2-phenylindole (DAPI). B, frequency of foci per cell. A549 cells were incubated with doxorubicin for 48 hours in the presence or absence of roscovitine.
g-H2AX foci were counted by eye in >100 cells by capturing images of randomly chosen fields. Columns are divided into fractions of cells containing from1to10 foci (class I),
from11to15 foci (class II), and from16 to 20 foci (class III). P V 0.01, for class I (unpaired Student’s t test).
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Fig. 6. Effects of roscovitine onhistone H2AX phosphorylation and on pRb activation. Left, A549 (A), H1299 (B), HEC1B (C), and HCT116 (D) cells were incubated with
doxorubicin for 48 hours in the presence or absence of roscovitine. Cells were immunostained with an anti-g-H2AX monoclonal antibody followed by secondary fluorescein
conjugate antibodies and analyzed by flow cytometry. I, control (gray) versus doxorubicin-treated cells (bold line); II, doxorubicin only (gray) versus cells treated with
doxorubicin + roscovitine (bold line). Right, pRb phosphorylationwas analyzed byWestern blot using a pan-pRb antibody.
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protein kinase pathway (18), and inhibition of transcription
(19). Because roscovitine dramatically sensitizes H1299 cells to
doxorubicin, we decided to further investigate the role of Cdks
in chemosensitization. We used tetracycline-inducible clones
expressing a dn-K2 (13). We reported previously that over-
expression of dn-K2 at high levels in H1299 cells results in G1
cell cycle arrest and expression of several markers of premature
senescence (20). Therefore, to mimic the effects of low
concentrations of roscovitine, we selected three clones with
very low dn-K2 expression; accordingly, induction of dn-K2
only slightly affected the cell cycle distribution of asynchro-
nously growing H1299 cells (data not shown). Expression of dn-
K2 enhanced the G2 arrest imposed by doxorubicin in all clones
(data not shown). More importantly, overexpression of dn-
K2 inhibited the ability of doxorubicin-treated H1299 cells to
resume proliferation (Fig. 4C; P < 0.001), only slightly increasing
the fraction of SA-h-gal-positive cells (Fig. 4C). Clonogenic
assays confirmed the ability of dn-K2 to sensitize H1299 cells to
doxorubicin (Fig. 4D).
These data indicate that the chemosensitizing effect of
roscovitine, observed in H1299 cells, is mediated via Cdk
inhibition.
Chemoprotective and chemosensitizing effects of roscovitine
correlate with the extent of DNA damage. The ability of
roscovitine to reinforce the G1 checkpoint in A549 cells is likely
to be responsible for the increased resistance of the cells toward
doxorubicin. To further investigate the mechanism of action of
roscovitine, we examined the incidence of g-H2AX foci in
doxorubicin-treated cells. g-H2AX is a sensitive signal for the
detection of DNA DSBs (21, 22) and the number of g-H2AX
foci increases linearly with the severity of the damage (23).
A549 cells were incubated either with doxorubicin alone or
with doxorubicin plus roscovitine and subsequently analyzed
for the presence of g-H2AX foci by immunofluorescence
microscopy. Analyses of control cells (untreated and roscovi-
tine-treated cells) showed one or two foci in a small proportion
of cells, whereas the majority of the population was negative for
g-H2AX (Fig. 5A; data not shown). Exposure of A549 cells to
doxorubicin resulted in the accumulation of clearly detectable
g-H2AX foci as shown in Fig. 5A. Quantitative analysis of
g-H2AX foci distribution, in >70 nuclei, showed a significant
accumulation of cells with reduced number of foci (6-10
foci per cell) in the presence of roscovitine compared with
doxorubicin alone (Fig. 5B).
We next analyzed H2AX phosphorylation by flow cytometry.
Flow cytometric analysis of g-H2AX is an accurate method of
measuring DNA DSBs (21) and represents a sensitive indicator
of clonogenic response to chemotherapy (24). Increased
intensity of fluorescence in doxorubicin-treated cells compared
with controls was readily detected by flow cytometry (Fig. 6A,
left, I). Analyses of g-H2AX in doxorubicin versus doxorubicin
plus roscovitine–treated cells confirmed the accumulation
of cells with low fluorescence in the presence of roscovitine
(Fig. 6A, left, II). These data strongly suggest a chemoprotective
effect of roscovitine in A549 cells. Because roscovitine sensitizes
H1299 cells to doxorubicin, combined treatment should
increase the incidence of g-H2AX foci in these cells. Indeed,
combination of roscovitine and doxorubicin results in a clear
shift of g-H2AX fluorescence toward higher intensity in H1299
cells (Fig. 6B, left, II).
These data indicate that roscovitine modulates the extent of
doxorubicin-induced DNA damage in tumor cells either
increasing the susceptibility to doxorubicin (H1299 cells) or
reinforcing G1 checkpoint and survival programs (A549 cells).
We decided to extend these observations to other carcinoma
lines. Because the effect of roscovitine on cell survival in A549
versus H1299 correlates with the ability of roscovitine to
modulate doxorubicin-dependent G1 checkpoint, we first
analyzed cell cycle distribution of a panel of carcinoma cells
treated either with doxorubicin or with doxorubicin plus
roscovitine. In the majority of the cell lines analyzed,
roscovitine enhanced the doxorubicin-dependent G2-M accu-
mulation (Table 1). This effect was reproducibly detected even
in cells in which doxorubicin alone induces a substantial
accumulation in G2-M (HeLa, SW480, and MDA-MB-231).
Reinforcement of the G1 checkpoint was detected in A549 and
HEC1B cells (Table 1). The effect of roscovitine does not
correlate with the p53 status of the cells (Table 1).
To confirm the correlation between cell cycle effect and DNA
DSBs modulation, we examined g-H2AX in HEC1B and
HCT116 cells. In line with the cell cycle data, combined
treatment with roscovitine and doxorubicin decreases the
phosphorylation of histone H2AX in HEC1B cells (Fig. 6C,
left, II), whereas it increases DSBs in HCT116 (Fig. 6D, left, II).
Table 1. Cell cycle distribution of adenocarcinoma cells treated with either doxorubicin alone (50 nmol/L) or with
doxorubicin in combinationwith roscovitine (10 Amol/L) for 48 hours
Cell lines Doxorubicin Doxorubicin + roscovitine p53 Status
G1 (%) G2-M (%) G1 (%) G2-M (%)
H1299 (lung) 20 55 13 61 /
HCT116 (colon) 37 56 13 79 +/+
MCF-7 (breast) 65 34 45 51 +/+
HeLa (cervix) 12 83 1 86 Human papillomavirus E6
SW480 (colon) 10 72 6 82 /
MDA-MB-231 (breast) 2 80 1 85 /
A549 (lung) 20 74 32 65 +/+
HEC1B (endometrium) 3 89 17 61 ND
NOTE: ND, not determined.
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Fig. 7. Effects of roscovitine on DNA-PK activity and homologous recombination. A, triplicate samples of H1299 cells were incubated either with doxorubicin or with
roscovitine + doxorubicin for 48 hours. DNA-PK activity was assessed onnuclear extracts and enzyme activity was normalized to Ku80 protein. Columns, mean; bars, SE;
B, HeLa cells were transiently transfectedwith either control vector (CMV) or I-SceI endonuclease in the absence or presence of10 Amol/L roscovitine (Rosco).The efficiency
of homologous recombinationwas estimated by flow cytometry. Columns, mean of three independent experiments; bars, SE. P V 0.01, unpaired Student’s t test. C, HeLa
cells were transiently cotransfectedwith I-SceI endonuclease together with either dnK2 or dnK1or empty control vector (CMV).The efficiency of homologous recombination
was estimated by flow cytometry. Columns, mean of three independent experiments; bars, SE. P < 0.001, for dnK2; P = 0.001, for dnK1 (unpaired Student’s t test).D, HeLa
cells were transiently cotransfected with I-SceI endonuclease together with either empty control vector or Cdk2 in a1:1or1:2 ratio.The efficiency of homologous
recombinationwas estimatedby flow cytometry. Columns, meanof three independent experiments; bars, SE.P V 0.01, unpaired Student’s t test. E, HeLa cells were transiently
cotransfected with I-SceI endonuclease together with either empty control vector or dnK2 or dnK1or Cdk2. Untransfected cells were used as control. Expression of
transfected proteins was assessed byWestern blot using anti-Cdk2 and anti-Cdc2 antibodies.
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These findings show a general ability of roscovitine to
modulate the extent of doxorubicin-induced DNA damage in
tumor cells, which ultimately affects the outcome of treatment.
However, roscovitine seems to either synergize or antagonize
with doxorubicin in different cells. Because pRb plays a key role
in G1 checkpoint (25) and is also required for intra-S response
to DNA damage (26, 27), we analyzed pRb phosphorylation
status in A549, HEC1B, H1299, and HCT116 cells. An
accumulation of hypophosphorylated, active pRb was readily
detected in A549 and HEC1B cells incubated with doxorubicin
(Fig. 6A and C, right). In contrast, no variation in pRb
phosphorylation pattern was observed in both H1299 and
HCT116 after treatment with doxorubicin (Fig. 6B and D,
right). These data suggest that the ability of roscovitine to
reinforce doxorubicin-dependent G1 checkpoint may require
active pRb.
Roscovitine modulates DNA repair pathways in doxorubicin-
treated cells. The results described indicate that roscovitine can
sensitize certain tumor cells to doxorubicin, increasing the
amount of DNA DSBs. There are two main pathways for DNA
DSBs repair: homologous recombination and nonhomologous
end-joining (NHEJ; ref. 28), which cooperate in vivo (29). In a
previous study (30), the ability of roscovitine to negatively
modulate NHEJ pathway in cells treated with ionizing radiation
has been reported. Therefore, we analyzed the activity of DNA-
PK in H1299 cells treated either with doxorubicin alone or
with doxorubicin plus roscovitine. We found that roscovitine
decreases DNA-PK activity in doxorubicin-treated H1299
by f40% (Fig. 7A). Western blot analyses confirmed (30) that
roscovitine affect neither Ku70 nor Ku80 protein levels (data
not shown). These results confirm that roscovitine negatively
modulates DNA-PK activity and inhibits NHEJ repair pathway
in H1299 cells.
In mammalian cells, the NHEJ pathway predominates during
G0 and G1 phases, whereas homologous recombination is
preferentially active in S and G2 phases (31, 32). Because the
chemosensitizing effect of roscovitine enhanced G2-M accumu-
lation, we decided to evaluate whether the homologous
recombination repair pathway was affected by roscovitine
using an in vivo recombination assay system.
We used a HeLa cell line that carries an integrated copy of a
GFP recombination reporter construct. The I-SceI restriction
endonuclease is used to introduce a DSB in the reporter gene.
Repair of the reporter gene by homologous recombination
leads to GFP expression, which is quantitatively analyzed by
flow cytometry.
We transiently transfected HeLa cells with I-SceI endonuclease
or with a control, empty vector, in the absence or presence of
10 Amol/L roscovitine and determined the efficiency of
homologous recombination by flow cytometry. As shown in
Fig. 7B, 10 Amol/L roscovitine reduced the efficiency of
recombinational repair by f30% (P V 0.01). No effects of
roscovitine on transfection efficiency of control plasmids in
HeLa cells were observed (data not shown). To further
substantiate a role for Cdks in modulation of homologous
recombination repair, HeLa cells were transiently cotransfected
with I-SceI endonuclease together with either dn-K2 or dn-K1
(13) or empty vector. Flow cytometric analyses show that tran-
sient expression of dn-K2 inhibited recombinational repair
by f50% (Fig. 7C; P < 0.001), whereas dn-K1 inhibited repair
by f40% (Fig. 7C; P = 0.001). Furthermore, cotransfection of
I-SceI endonuclease with increasing amounts of Cdk2 resulted
in a dose-dependent increase in homologous recombination
repair (Fig. 7D; P V 0.01). Expression of transfected proteins was
assessed by Western blot (Fig. 7E). These results indicate that
inhibition of Cdk2 and Cdk1 activity, either by pharmacologic
agent or by dominant-negative isoforms, results in decreased
homologous recombination repair.
These experiments show that roscovitine affects DNA repair
processes in tumor cells, which results in tumor chemo-
sensitization.
Effects of roscovitine and etoposide on H1299 cells. To extend
the above observations to other topoisomerase II inhibitors,
H1299 cells were treated with either roscovitine or etoposide
alone or in combination for 48 hours and then analyzed by
flow cytometry. As shown in Fig. 8A, etoposide-treated cells
largely accumulated in the G2-M phase. Simultaneous treat-
ment with roscovitine and etoposide favored the G2-M
accumulation of H1299 cells (Fig. 8A). To confirm the
correlation between cell cycle effect and DNA DSBs modula-
tion, we examined H2AX phosphorylation. In line with the cell
cycle data, combined treatment with roscovitine and etoposide
increased DSBs in H1299 cells (Fig. 8B, left, II). These data
indicate that roscovitine also modulates the extent of etopo-
side-induced DNA damage in H1299 cells.
Reinforcement of pRb-dependent G1 arrest in etoposide-treated
A549 cells by roscovitine. We next investigated the ability of
roscovitine to modulate etoposide-dependent G1 checkpoint in
A549 cells. Because etoposide is not as effective as doxorubicin
in inducing a G1 arrest response (33), we first evaluated the
effect of different sublethal concentrations of etoposide on pRb
activation. Treatment of A549 cells with 1 Amol/L etoposide
only induced partial dephosphorylation in pRb protein,
whereas a higher concentration (5 Amol/L) was effective in
activating pRb (Fig. 8C; data not shown). Both concentrations
resulted in accumulation of A549 cells in G2-M phase (Fig. 8D).
Next, we assessed the ability of roscovitine to reinforce the
G1 checkpoint in etoposide-treated A549 cells. Interestingly,
whereas roscovitine effectively reinforced the G1 arrest in cells
treated with the higher concentration of etoposide (Fig. 8D),
simultaneous treatment with 1 Amol/L etoposide and roscovi-
tine favored the G2-M accumulation (Fig. 8D). These data
Fig. 8. Effects of etoposide and roscovitine in H1299 and in A549 cells.A, H1299 cells were incubated with roscovitine (10 Amol/L), etoposide (1 Amol/L), or both for
48 hours. Numbers, percentage of cells in G1, S, or G2-M phase.The percentage of apoptotic, sub-G1cells, estimated by flow cytometric analyses, never exceeded 5% in all
conditions studied. B, H1299 cells were incubated with1 Amol/L etoposide for 48 hours in the presence or absence of roscovitine. Cells were immunostained with an
anti-g-H2AX monoclonal antibody followed by secondary fluorescein conjugate antibodies and analyzed by flow cytometry. I, control (black line) versus etoposide-treated
cells (red line); II, etoposide only (black line) versus cells treatedwith etoposide + roscovitine (red line).C, pRb phosphorylation status in A549 cells was analyzedbyWestern
blot using a pan-pRb antibody.D, A549 cells were incubated with roscovitine, etoposide, or both for 48 hours. Numbers, percentage of cells in G1, S, or G2-M phase.The
percentage of apoptotic, sub-G1cells, estimated by flow cytometric analyses, never exceeded 5% in all conditions studied. E, A549 cells were incubated with 5 Amol/L
etoposide for 48 hours in the presence or absence of roscovitine. Cells were immunostained with an anti-g-H2AX monoclonal antibody followed by secondary fluorescein
conjugate antibodies and analyzed by flow cytometry. I, control (black line) versus etoposide-treated cells (red line); II, etoposide only (black line) versus cells treated with
etoposide + roscovitine (red line).
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further suggest that the ability of roscovitine to reinforce DNA
damage–dependent G1 checkpoint may require active pRb.
Finally, we examined the effect of increased G1 arrest on the
incidence of g-H2AX foci in etoposide-treated A549 cells.
Combination of roscovitine and 5 Amol/L etoposide substan-
tially decreased DSBs in A549 cells (Fig. 8E, left, II). In contrast,
roscovitine did not change H2AX phosphorylation in cells
treated with 1 Amol/L etoposide (data not shown). These data
further suggest that the chemoprotective effect of roscovitine in
A549 cells requires pRb activation.
Discussion
Because inhibition of Cdk activity seems to be a major event
in cellular responses to sublethal DNA damage, we investigated
the effects of roscovitine, a pharmacologic inhibitor of Cdk
activity, on doxorubicin-induced senescence in human carci-
noma cells. Our results show that treatment of A549 lung
adenocarcinoma cells with sublethal doses of doxorubicin
induces senescence in a substantial fraction of the cells.
Roscovitine significantly potentiates this response, increasing
the fraction of SA-h-gal-positive cells by f30%. In addition, a
consistent increase in clonogenic survival was detected when
cells were treated with roscovitine and doxorubicin compared
with doxorubicin alone. These data together indicate a
chemoprotective effect of roscovitine in A549 cells. Similar
results were obtained in HEC1B cells.
The protective effect of roscovitine is correlated to a cell cycle
inhibitory function, which results in an increased cell cycle
block at G1 phase. G1 cell cycle arrest has been correlated
previously with decreased susceptibility to chemotherapeutic
drugs (34, 35). In addition, expression of p21CIP and p16INK4
(which results in G1 arrest) was reported to negatively regulate
apoptosis (5, 36). Up-regulation of p21CIP has also been
associated with drug resistance (37) and p21CIP has been
shown to play a key role in G1 checkpoint maintenance (25).
pRb represents a key target for Cdk inhibitors in G1 checkpoint.
In addition, recent data show a critical role for pRb in DNA
damage–dependent intra-S checkpoint (26, 27). Consistent
with the up-regulation of p21CIP, hypophosphorylated, active
isoforms of pRb accumulate in both A549 and HEC1B cells
treated with doxorubicin. Analyses of cell cycle regulators in
these cells suggest that roscovitine reinforces the G1 checkpoint
by direct inhibition of Cdk2 and Cdk1. Hence, roscovitine
seems to synergize with a p21CIP-dependent, pRb-mediated
G1 cell cycle arrest.
The augmentation of G1 arrest correlated with the extent of
DNA damage: roscovitine reduces the amount of g-H2AX foci
in A549 and HEC1B cells. The negative correlation between
G1 arrest and DNA damage is further supported by analyses of
other cell lines. In fact, lack of G1 arrest and augmentation of
G2-M accumulation in other cells correlates with an increase in
DNA DSBs. By lowering the level of doxorubicin-induced DNA
damage roscovitine may easily facilitate both premature
senescence and repair programs in A549 and HEC1B cells,
thus inducing chemoprotection.
Analyses of H1299 cells highlighted an unexpected ability
of roscovitine to potentiate both doxorubicin and etoposide
cytotoxicity. Our data show that a nontoxic concentration of
roscovitine, with minimal effects on cell proliferation, renders
H1299 cells significantly more susceptible to doxorubicin. In
these cells, roscovitine does not modulate senescence but
markedly reduces the capacity of cells to repair damage and to
resume proliferation after treatment. As discussed above, this
sensitizing effect of roscovitine correlates with an increased
accumulation of cells in G2-M. This potentiation of G2-M
blockade is likely secondary to increased DNA damage.
Augmentation of DSBs in roscovitine plus doxorubicin–
treated cells would lead to enhanced G2-M checkpoint
activation and to G2-M-phase cell accumulation. These
unexpected findings were extended to several other carcinoma
cells in which combined treatment with roscovitine and
doxorubicin, or etoposide, was found to enhance G2-M
accumulation, to increase the amount of g-H2AX foci, and
to inhibit DNA repair.
Two main repair pathways, homologous recombination and
NHEJ, cooperate to repair DNA DSBs (28). We investigated the
ability of roscovitine to modulate these two processes in
doxorubicin-treated cells. We first confirmed the ability of
roscovitine to negatively modulate DNA-PK activity in H1299
cells (30). Then, we investigated the effect of roscovitine on
homologous recombination repair. Our data show that rosco-
vitine significantly reduces the efficiency of recombinational
repair and identify a novel mechanism of action by which
roscovitine affects tumor cells: inhibition of DNA DSBs repair.
Pleiotropic effects of roscovitine have been reported in human
tumor cell lines (17–19), which prompted us to further
substantiate the role of Cdk2 and Cdk1 kinases as targets of
roscovitine in tumor chemosensitization. Experiments with
inducible dn-K2 clones indicate that loss of Cdk2 and Cdk1
activity is indeed responsible for the chemosensitizing effect of
roscovitine. Overexpression of dn-K2 in H1299 cells, in fact,
potentiated doxorubicin-induced G2-M arrest and inhibited
recovery of the cells after treatment (Fig. 4). It is worth noting
that overexpression of dn-K2 results in both Cdk2 and Cdk1
inhibition (13). Furthermore, analyses of homologous recom-
bination in HeLa cells transiently overexpressing either dn-K2 or
dn-K1 or Cdk2 confirmed a role for Cdks in modulation
of DNA repair processes (Fig. 7). Recently, a role for Cdk in
the control of DNA repair pathways has been shown in yeast cells
(38, 39).
These data support a therapeutic potential for roscovitine
combined with doxorubicin in tumor treatment. An ability of
various pharmacologic Cdk inhibitors to enhance cytotoxicity
has been noted in other tumor cell systems and has been
correlated to lack of functional p53 protein (30, 34). In
contrast, the chemosensitizing effect that we report involves
both p53/ (H1299, HeLa, SW480, and MDA-MB-231) and
p53+/+ (HCT116 and MCF-7) cell lines. However, it is worth
noting that the doses of doxorubicin used in this study are
sublethal and almost exclusively activate senescence and repair
pathways. Therefore, combined treatment with roscovitine and
doxorubicin in our system seems to increase a nonapoptotic,
delayed death response likely due to mitotic catastrophe.
Hence, combined treatment of roscovitine and DNA-damaging
agents not only enhances drug-induced apoptosis (40, 41) but
also effectively hampers the recovery of mildly damaged tumor
cells after treatment.
In conclusion, the results described above indicate that
roscovitine, by hindering both homologous recombination
and NHEJ repair processes, has the potential to inhibit
recovery of mildly damaged tumor cells after doxorubicin
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treatment and to increase the susceptibility of tumor cells to
chemotherapy.
However, analyses of A549 and HEC1B cells suggests that
in some tumor cell lines the cell cycle inhibitory function
of roscovitine prevails on the DNA repair inhibitory activity.
In these settings, roscovitine can reinforce DNA damage–
dependent G1 checkpoint, favoring survival programs. This
raises the possibility that treatment with roscovitine might
promote resistance to chemotherapeutic drugs in some tumors.
To investigate possible mechanisms for the differential effects
of roscovitine, we evaluated pRb phosphorylation status in
A549, HEC1B, H1299, and HCT116 cells. In line with its
central role in G1 cell cycle checkpoint, activation of pRb
became readily apparent in both A549 and HEC1B cells after
incubation with doxorubicin (or etoposide). Surprisingly,
H1299 and HCT116 cells, treated in the same way, did not
show any significant accumulation of hypophosphorylated
pRb, suggesting that DNA damage–dependent activation of
pRb in these cells is compromised. pRb activation defect in
tumor cell lines has been reported previously (42). These
data suggest that the ability of roscovitine to reinforce the
doxorubicin-dependent (or etoposide-dependent) G1 check-
point might require the presence of active pRb. This work
represents a novel mechanism for combined chemotherapy
that may have widespread application to treating carcinomas.
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